Cargando…

Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib

Variability in the molecular response to frontline tyrosine kinase inhibitor (TKI) therapy in chronic myeloid leukemia may be partially driven by differences in the level of kinase inhibition induced. We measured in vivo BCR::ABL1 kinase inhibition (IVKI) in circulating mononuclear cells after 7 day...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kok, Chung H., Saunders, Verity A., Dang, Phuong, Shanmuganathan, Naranie, White, Deborah, Branford, Susan, Yeung, David, Hughes, Timothy P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495334/ https://www.ncbi.nlm.nih.gov/pubmed/37696829 http://dx.doi.org/10.1038/s41408-023-00917-4

Ejemplares similares

S151: COMBINATION OF LARGE SPLEEN AND LOW IN VIVO KINASE INHIBITION IS AN EARLY PREDICTOR OF INFERIOR MOLECULAR RESPONSE AND POOR OUTCOMES IN CHRONIC MYELOID LEUKAEMIA
por: Kok, Chung, et al.
Publicado: (2023)

Genomic Mechanisms Influencing Outcome in Chronic Myeloid Leukemia
por: Fernandes, Adelina, et al.
Publicado: (2022)

BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia
por: Pagani, Ilaria S., et al.
Publicado: (2018)

Increased peroxisome proliferator-activated receptor γ activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cells
por: Wang, Jueqiong, et al.
Publicado: (2017)

Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemia
por: Irani, Yazad D., et al.
Publicado: (2023)

Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention
por: Shanmuganathan, Naranie, et al.
Publicado: (2023)

NGS in CML - New standard diagnostic procedure?
por: Branford, Susan, et al.
Publicado: (2019)

Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation
por: Adnan Awad, Shady, et al.
Publicado: (2022)

Chronic myeloid leukemia with marked splenomegaly and pseudo-Gaucher cells
por: Yang, Hyung-Seok, et al.
Publicado: (2013)

Imatinib in Chronic Myeloid Leukemia: an Overview
por: Sacha, Tomasz
Publicado: (2014)

Solute Carrier Family 29A1 Mediates In Vitro Resistance to Azacitidine in Acute Myeloid Leukemia Cell Lines
por: Kutyna, Monika M., et al.
Publicado: (2023)

Imatinib in chronic myeloid leukemia elderly patients
por: Gugliotta, Gabriele, et al.
Publicado: (2011)

Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase
por: Mughal, Tariq I, et al.
Publicado: (2010)

Dasatinib - clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia
por: Conchon, Monika, et al.
Publicado: (2011)

Analysis of adverse drug reactions of imatinib in chronic myeloid leukemia patients: An Eastern Indian experience
por: Swain, Trupti Rekha, et al.
Publicado: (2022)

The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression in vitro
por: Eadie, Laura N., et al.
Publicado: (2018)

Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia
por: Ramchandren, Radhakrishnan, et al.
Publicado: (2009)

Monitoring imatinib plasma concentrations in chronic myeloid leukemia
por: Martins, Darlize Hübner, et al.
Publicado: (2011)

Targeted treatment of chronic myeloid leukemia: role of imatinib
por: Tamascar, Ila, et al.
Publicado: (2009)

Therapy of Chronic Myeloid Leukemia: Twilight of the Imatinib Era?
por: Trela, Ewelina, et al.
Publicado: (2014)

Renal tuberculosis in an imatinib-treated chronic myeloid leukemia
por: Chandra, Abhilash, et al.
Publicado: (2020)

Adverse drug reactions of imatinib in patients with chronic myeloid leukemia: A single-center surveillance study
por: Francis, Jose, et al.
Publicado: (2015)

Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells
por: Lu, Ying, et al.
Publicado: (2016)

Measurable residual disease in chronic myeloid leukemia
por: Branford, Susan, et al.
Publicado: (2022)

Adverse drug reactions of imatinib in patients with chronic myeloid leukemia: A single-center surveillance study: Erratum
Publicado: (2015)

Peripheral neuropathy associated with imatinib therapy for chronic myeloid leukemia
por: Kavanagh, Simon, et al.
Publicado: (2018)

Modelling Predictors of Molecular Response to Frontline Imatinib for Patients with Chronic Myeloid Leukaemia
por: Banjar, Haneen, et al.
Publicado: (2017)

Why is it critical to achieve a deep molecular response in chronic myeloid leukemia?
por: Branford, Susan
Publicado: (2020)

Allografting for Bosutinib, Imatinib, Nilotinib, Dasatinib, and Interferon Resistant Chronic Myeloid Leukemia without ABL Kinase Mutation
por: Uz, B., et al.
Publicado: (2011)

Kinase domain mutations and responses to dose escalation in chronic myeloid leukemia resistant to standard dose imatinib mesylate
por: Rajappa, Senthil, et al.
Publicado: (2013)

Late Emergence of an Imatinib-Resistant ABL1 Kinase Domain Mutation in a Patient with Chronic Myeloid Leukemia
por: Crampe, Mireille, et al.
Publicado: (2017)

Novel mutations in the kinase domain of BCR-ABL gene causing imatinib resistance in chronic myeloid leukemia patients
por: Chandrasekhar, Chodimella, et al.
Publicado: (2019)

Comparison of Dasatinib- and Imatinib-Related Cardiotoxic Adverse Events in Japanese Patients With Chronic Myeloid Leukemia and Gastrointestinal Stromal Tumor
por: Motokawa, Tetsufumi, et al.
Publicado: (2021)

Proteome Changes Induced by Imatinib and Novel Imatinib Derivatives in K562 Human Chronic Myeloid Leukemia Cells
por: Arvaniti, Katerina, et al.
Publicado: (2014)

Curcumin Decreases Viability and Inhibits Proliferation of Imatinib-Sensitive and Imatinib-Resistant Chronic Myeloid Leukemia Cell Lines
por: Bilajac, Esma, et al.
Publicado: (2022)

Initial Rate of BCR::ABL1 Decline for Response Prediction in Chronic Myeloid Leukemia
por: Branford, Susan
Publicado: (2022)

Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec(®), Gleevec™)
por: Henkes, Martin, et al.
Publicado: (2008)

Synergy between Proteasome Inhibitors and Imatinib Mesylate in Chronic Myeloid Leukemia
por: Hu, Zheng, et al.
Publicado: (2009)

An uneventful pregnancy and delivery, in a case with chronic myeloid leukemia on imatinib
por: Martin, Jovita, et al.
Publicado: (2011)

Imatinib resistance: a review of alternative inhibitors in chronic myeloid leukemia
por: Bitencourt, Roberta, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_m0coqnqr1rh6ldqpbqa4a49tnn